Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 30, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of common stock.
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 17, 2024.
- Edgemond exercised stock options at prices of $120.26 and $117.76.
- He sold shares at a price of $358.62.
- The transactions resulted in a change in Edgemond's beneficial ownership of United Therapeutics common stock and derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan suggests the insider is trading according to a pre-determined strategy to avoid accusations of insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the impact is likely to be limited.
Key Dates
| Date | Description |
|---|---|
| 03/15/2017 | Date stock options were exercisable |
| 03/15/2021 | Date stock options were exercisable |
| 05/17/2024 | Date the Rule 10b5-1 trading plan was entered into. |
| 09/30/2024 | Date of the stock option exercise and share sales. |
| 10/01/2024 | Date of signature on the Form 4 filing. |
| 03/15/2026 | Expiration date of stock options |
| 03/15/2027 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.